First Review of ESMO’s Magnitude of Clinical Benefit Scale Offers a Thumbs-Up

First Review of ESMO’s Magnitude of Clinical Benefit Scale Offers a Thumbs-Up
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a valuable tool to measure the importance of clinically meaningful benefits that can be expected from a new anti-cancer drug in both common and rare diseases. Data from ESMO-MCBS on common tumors already had been obtained by researchers at Medical University of Vienna (MUV), one of Europe's largest cancer centers, and the application of ESMO-MCBS in real-life context for rare tumors was presented recently at the ESMO 2016 Congress, held Oct. 7-11 in Denmark. "We assessed data on neuroendocrine tumors (NET), glioblastoma, sarcomas, thyroid, pancreatic, ovarian, head/neck and urothelial cancers," Barbara Kiesewetter, MD of MUV, said in a press release. "Data was analyzed in a three-step approach: we collected data on regimens in daily use at the MUV, then analyzed the data with the ESMO-MCBS as our second step, and finally we evaluated and discussed the data in terms of clinical feasibility and practicability in daily practice," she said. "We noted a phenomenon whereby the ESMO-MCBS particularly highlights the clinical benefit to be expected of new immunomodulatory drugs," she said. "This was also observed in our field testing on common tumor entities and may help us to implement these treatments in daily practice in the near future. We are particularly excited that new data on checkpoint inhibitors for rare entities is due to be available soon." Prior to ESMO-MCBS development, no standard tool was availabl
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *